Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Dose Dense/Dose Intense ABVD without Radiotherapy: A New Early Intensification Treatment Approach in Advanced-Stage Hodgkin Lymphoma. Ten Years Experience and Analysis of a Consecutive Series of 172 Previously Untreated Classic Hodgkin’s Lymphoma Patients

Filippo Russo, MD

Blood (2014) 124 (21): 1705.

https://doi.org/10.1182/blood.V124.21.1705.1705

Published: 2014

Journal Articles

Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as First-Line Treatment In High-Risk Peripheral T-Cell/NK Lymphomas: A Phase II Trial.

Gaetano Corazzelli, MD, Ferdinando Frigeri, MD, Gianpaolo Marcacci, MD, Cristina Becchimanzi, MD, Gaetana Capobianco, MD, Manuela Arcamone, MD, Emanuela Morelli, MD, Francesco Volzone, MD, Filippo Russo, MD, Antonio Pinto, MD

Blood (2010) 116 (21): 2829.

https://doi.org/10.1182/blood.V116.21.2829.2829

Published: 2010

Journal Articles

Biweekly Rituximab, Cyclophosphamide, Vincristine, Non-Pegylated Liposome-Encapsulated Doxorubicin (Myocet®) and Prednisone (R-COMP-14) as Induction Treatment in Poor R-IPI Risk Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) and Pre-Existing Heart Disease.

Ferdinando Frigeri, MD, Gaetano Corazzelli, MD, Manuela Arcamone, MD, Gaetana Capobianco, MD, Anna Lucania, MD, Cristina Becchimanzi, MD, Gianpaolo Marcacci, MD, Filippo Russo, MD, Maria Rosaria Villa, MD, Lucia Mastrullo, MD, Antonio Pinto, MD

Blood (2009) 114 (22): 1664.

https://doi.org/10.1182/blood.V114.22.1664.1664

Published: 2009

Journal Articles

Abnormally Elevated Levels of Serum Free-Immunoglobulin Light Chains Are Frequently Found in Classic Hodgkin Lymphoma (cHL) and Predict Outcome of Patients with Early Stage Disease.

Rosaria De Filippi, MD, PhD, Filippo Russo, MD, Giancarla Iaccarino, D.Sci, Stefania Crisci, D.Sci, Ferdinando Frigeri, Costantino Riemma, Alessandro Marchei, D.Sci, Rosa Calemma, D.Sci, Raffaele Di Francia, D.Pharm, Gianpaolo Marcacci, MD, Gaetano Corazzelli, MD, Gaetana Capobianco, MD, Cristina Becchimanzi, MD, Manuela Arcamone, MD, Barbara Amoroso, MD, Giuseppe Castello, MD, Antonio Pinto, MD

Blood (2009) 114 (22): 267.

https://doi.org/10.1182/blood.V114.22.267.267

Published: 2009

Journal Articles

Safety and Efficacy of Intrathecal Liposome-Encapsulated Cytarabine for Central Nervous System (CNS) Prophylaxis in Adult Patients with Burkitt and Atypical Burkitt Lymphoma Treated with the R-CODOX-M/R-IVAC (Magrath) Regimen: Results of a Phase II Study.

Ferdinando Frigeri, MD, Filippo Russo, MD, Manuela Arcamone, MD, Chiara Fraira, MD, Gennaro Russo, MD, Gaetana Capobianco, MD, Cristina Becchimanzi, MD, Arturo Cuomo, MD, Gianpaolo Marcacci, MD, Gennaro Esposito, MD, Rosaria De Filippi, MD, PhD, Gaetano Corazzelli, MD, Umberto Vitolo, MD, Antonio Pinto, MD

Blood (2009) 114 (22): 3716.

https://doi.org/10.1182/blood.V114.22.3716.3716

Published: 2009

Journal Articles

Dose-Dense(dd) ABVD and Dose-Dense/Dose-Intense(dd-di) ABVD in Newly Diagnosed Patients (pts), Intermediate- and Advanced-Stage with Classical Hodgkin's Lymphoma (cHL): Final Results.

Filippo Russo, MD, Gaetano Corazzelli, MD, Secondo Lastoria, MD, Gianpaolo Marcacci, MD, Ferdinando Frigeri, MD, Gaetana Capobianco, Cristina Becchimanzi, MD, Manuela Arcamone, MD, Antonio Pinto, MD

Blood (2009) 114 (22): 715.

https://doi.org/10.1182/blood.V114.22.715.715

Published: 2009

Journal Articles

Abnormalities in Serum Free-Immunoglobulin Light Chains Show a High and Differential Frequency among WHO Subtypes of B-Cell Non-Hodgkin’s Lymphoma (NHL) and May Turn of Value for Therapeutic Monitoring: A Study of 354 Newly Diagnosed Patients

Antonio Pinto, MD, Rosaria De Filippi, MD, PhD, Giancarla Iaccarino, D.Sci, Raffaele Di Francia, D.Sci, Mariarosaria Distinto, D.Sci, Ferdinando Frigeri, MD, PhD, Filippo Russo, MD, Alessandro Marchei, D.Sci, Barbara Amoroso, MD

Blood (2008) 112 (11): 2813.

https://doi.org/10.1182/blood.V112.11.2813.2813

Published: 2008

Journal Articles

The Brain Transcription Factor OTX1 Is Activated in Specific Non-Hodgkin Lymphoma Subtypes and Normally Expressed in a Germinal Center-Restricted Small Subpopulation of CD138 + Plasmacell-Like Cells.

Filippo Russo, MD, Daniela Omodei, Dario Acampora, Rosaria De Filippi, MD, Valeria Severino, Raffaele Di Francia, Ferdinando Frigeri, MD, Pietro Mancuso, Anna De Chiara, MD, Renato Franco, MD, Stefano Casola, Antonio Pinto, Antonio Simeone

Blood (2007) 110 (11): 2618.

https://doi.org/10.1182/blood.V110.11.2618.2618

Published: 2007

Journal Articles

Dose Dense and Dose Intense ABVD (dd-di ABVD) in Advanced and Intermediate-Stage Hodgkin’s Lymphoma (HL).

Filippo Russo, MD, Gaetano Corazzelli, MD, Ferdinando Frigeri, MD, Gianpaolo Marcacci, MD, Antonio Pinto

Blood (2007) 110 (11): 2324.

https://doi.org/10.1182/blood.V110.11.2324.2324

Published: 2007

Journal Articles

Cladribine (2-CDA) Plus Sequential Rituximab in Newly Diagnosed Disseminated Extranodal Marginal Zone B-Cell Lymphomas. A Phase II Study.

Gaetano Corazzelli, MD, Gaetana Capobianco, MD, Filippo Russo, MD, Oreste Villani, MD, Patrizia Vassallo, MD, Antonio Pinto, MD

Blood (2006) 108 (11): 2761.

https://doi.org/10.1182/blood.V108.11.2761.2761

Published: 2006

Journal Articles

100% of Complete Response (CR) and Survival (FFP, OS) in Newly Diagnosed Patients with Advanced- and Intermediate-Stage Hodgkin’s Lymphoma (HL) Treated with Six Cycles of Dose-Dense, Dose-Intense (DD-DI) ABVD without Radiotherapy (RT).

Filippo Russo, MD, Gaetano Corazzelli, MD, Ferdinando Frigeri, MD, Secondo LaStoria, Antonio Pinto

Blood (2006) 108 (11): 2476.

https://doi.org/10.1182/blood.V108.11.2476.2476

Published: 2006

Journal Articles

The Impact of Relative Dose Intensity on Response and Survival in a Series of 180 Newly Diagnosed Patients with Hodgkin’s Lymphoma.

Filippo Russo, MD, Gino Svanera, MD, Paola Della Cioppa, MD, Gaetano Corazzelli, MD, Ferdinando Frigeri, MD, Gaetana Capobianco, MD, Secondo LaStoria, MD, Antonio Pinto, MD

Blood (2005) 106 (11): 2671.

https://doi.org/10.1182/blood.V106.11.2671.2671

Published: 2005

Journal Articles

Gemcitabine, Ifosfamide, Oxaliplatin and Rituximab (R-GIFOX), a New Effective Cytoreductive/Mobilizing Salvage Regimen for Relapsed and Refractory Aggressive Non-Hodgkin’s Lymphoma: Results of a Pilot Study.

Gaetano Corazzelli, MD, Filippo Russo, MD, Gaetana Capobianco, MD, Gianpaolo Marcacci, MD, Paola Della Cioppa, MD, Antonio Pinto, MD

Blood (2005) 106 (11): 940.

https://doi.org/10.1182/blood.V106.11.940.940

Published: 2005

NARROW

Dose Dense/Dose Intense ABVD without Radiotherapy: A New Early Intensification Treatment Approach in Advanced-Stage Hodgkin Lymphoma. Ten Years Experience and Analysis of a Consecutive Series of 172 Previously Untreated Classic Hodgkin’s Lymphoma Patients

Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as First-Line Treatment In High-Risk Peripheral T-Cell/NK Lymphomas: A Phase II Trial.

Biweekly Rituximab, Cyclophosphamide, Vincristine, Non-Pegylated Liposome-Encapsulated Doxorubicin (Myocet®) and Prednisone (R-COMP-14) as Induction Treatment in Poor R-IPI Risk Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) and Pre-Existing Heart Disease.

Abnormally Elevated Levels of Serum Free-Immunoglobulin Light Chains Are Frequently Found in Classic Hodgkin Lymphoma (cHL) and Predict Outcome of Patients with Early Stage Disease.

Safety and Efficacy of Intrathecal Liposome-Encapsulated Cytarabine for Central Nervous System (CNS) Prophylaxis in Adult Patients with Burkitt and Atypical Burkitt Lymphoma Treated with the R-CODOX-M/R-IVAC (Magrath) Regimen: Results of a Phase II Study.

Dose-Dense(dd) ABVD and Dose-Dense/Dose-Intense(dd-di) ABVD in Newly Diagnosed Patients (pts), Intermediate- and Advanced-Stage with Classical Hodgkin's Lymphoma (cHL): Final Results.

Abnormalities in Serum Free-Immunoglobulin Light Chains Show a High and Differential Frequency among WHO Subtypes of B-Cell Non-Hodgkin’s Lymphoma (NHL) and May Turn of Value for Therapeutic Monitoring: A Study of 354 Newly Diagnosed Patients

The Brain Transcription Factor OTX1 Is Activated in Specific Non-Hodgkin Lymphoma Subtypes and Normally Expressed in a Germinal Center-Restricted Small Subpopulation of CD138 + Plasmacell-Like Cells.

Dose Dense and Dose Intense ABVD (dd-di ABVD) in Advanced and Intermediate-Stage Hodgkin’s Lymphoma (HL).

Cladribine (2-CDA) Plus Sequential Rituximab in Newly Diagnosed Disseminated Extranodal Marginal Zone B-Cell Lymphomas. A Phase II Study.

100% of Complete Response (CR) and Survival (FFP, OS) in Newly Diagnosed Patients with Advanced- and Intermediate-Stage Hodgkin’s Lymphoma (HL) Treated with Six Cycles of Dose-Dense, Dose-Intense (DD-DI) ABVD without Radiotherapy (RT).

The Impact of Relative Dose Intensity on Response and Survival in a Series of 180 Newly Diagnosed Patients with Hodgkin’s Lymphoma.

Gemcitabine, Ifosfamide, Oxaliplatin and Rituximab (R-GIFOX), a New Effective Cytoreductive/Mobilizing Salvage Regimen for Relapsed and Refractory Aggressive Non-Hodgkin’s Lymphoma: Results of a Pilot Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only